Whole-genome bisulfite DNA sequencing of a DNMT3B mutant patient

Epigenetics

Volumn 7, Issue 6, 2012, Pages 542-550

  Heyn, Holger ^a   Vida, Enrique ^b,c   Sayols, Sergi ^a   Sanchez Mut, Jose V ^a   Moran, Sebastian ^a   Medina, Ignacio ^b   Sandoval, Juan ^a   Simó Riudalbas, Laia ^a   Szczesna, Karolina ^a   Huertas, Dori ^a   Gatto, Sole ^d   Matarazzo, Maria R ^d   Dopazo, Joaquin ^b,c   Esteller, Manel ^a,e,f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

CpG island; DNA methylation; DNA methyltransferase; DNMT3B; Histone; Immunodeficiency; Transposon; Whole genome bisulfite sequencing; X chromosome

Indexed keywords

HISTONE H3; HISTONE H3K4ME1; RIBOSOME RNA; UNCLASSIFIED DRUG;

ARTICLE; CHILD; DNA METHYLATION; DNA METHYLTRANSFERASE 3B GENE; DNA SEQUENCE; EPIGENETICS; FACE MALFORMATION; FEMALE; GENE; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; GENOME; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNODEFICIENCY CENTROMERE INSTABILITY AND FACIAL ANOMALIES SYNDROME; NORMAL HUMAN; PRESCHOOL CHILD;

EID: 84861920481     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.20523     Document Type: Article

References (45)

1. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28:1057-68; PMID:20944598; http://dx.doi.org/10.1038/nbt.1685.
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; http://dx.doi.org/10.1056/NEJMra072067.
3. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39:457-66; PMID:17334365; http://dx.doi.org/10.1038/ng1990.
4. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69:915-26; PMID:1606615; http://dx.doi.org/10.1016/0092-8674(92)90611-F.
5. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402:187-91; PMID:10647011; http://dx.doi.org/10.1038/46214.
6. Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 1999; 96:14412-7; PMID:10588719; http://dx.doi.org/10.1073/pnas.96.25.14412.
7. Chouery E, Abou-Ghoch J, Corbani S, El Ali N, Korban R, Salem N, et al. A novel deletion in ZBTB24 in a Lebanese family with immunodeficiency, centromeric instability and facial anomalies syndrome type 2. Clin Genet 2011; PMID:21906047; http://dx.doi.org/10.1111/j.1399-0004.2011.01783.x.
8. de Greef JC, Wang J, Balog J, den Dunnen JT, Frants RR, Straasheijm KR, et al. Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability and facial anomalies syndrome type 2. Am J Hum Genet 2011; 88:796-804; PMID:21596365; http://dx.doi.org/10.1016/j.ajhg.2011.04.018.
9. Brun ME, Lana E, Rivals I, Lefranc G, Sarda P, Claustres M, et al. Heterochromatic genes undergo epigenetic changes and escape silencing in immunodeficiency, centromeric instability, facial anomalies (ICF) syndrome. PLoS One 2011; 6:19464; PMID:21559330; http://dx.doi.org/10.1371/journal.pone.0019464.
10. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99:247-57; PMID:10555141; http://dx.doi. org/10.1016/S0092-8674(00)81656-6.
11. Prada D, González R, Sánchez L, Castro C, Fabián E, Herrera LA. Satellite 2 demethylation induced by 5-azacytidine is associated with missegregation of chromosomes 1 and 16 in human somatic cells. Mutat Res 2012; 729:100-5; PMID:22032830; http://dx.doi.org/10.1016/j.mrfmmm.2011.10.007.
12. Martins-Taylor K, Schroeder DI, Lasalle JM, Lalande M, Xu RH. Role of DNMT3B in the regulation of early neural and neural crest specifiers. Epigenetics: Official Journal of the DNA Methylation Society 2012; 7.
13. Jin B, Tao Q, Peng J, Soo HM, Wu W, Ying J, et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum Mol Genet 2008; 17:690-709; PMID:18029387; http://dx.doi.org/10.1093/hmg/ddm341.
14. Gatto S, Della Ragione F, Cimmino A, Strazzullo M, Fabbri M, Mutarelli M, et al. Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics 2010; 5:427-43; PMID:20448464; http://dx.doi.org/10.4161/epi.5.5.11999.
15. Matarazzo MR, De Bonis ML, Gregory RI, Vacca M, Hansen RS, Mercadante G, et al. Allelic inactivation of the pseudoautosomal gene SYBL1 is controlled by epigenetic mechanisms common to the X and Y chromosomes. Hum Mol Genet 2002; 11:3191-8; PMID:12444103; http://dx.doi.org/10.1093/hmg/11.25.3191.
16. Wijmenga C, Hansen RS, Gimelli G, Björck EJ, Davies EG, Valentine D, et al. Genetic variation in ICF syndrome: evidence for genetic heterogeneity. Hum Mutat 2000; 16:509-17; PMID:11102980; http://dx.doi.org/10.1002/1098-1004(200012)16:6509::AIDHUMU83.0.CO;2-V.
17. Jiang YL, Rigolet M, Bourc'his D, Nigon F, Bokesoy I, Fryns JP, et al. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum Mutat 2005; 25:56-63; PMID:15580563; http://dx.doi.org/10.1002/humu.20113.
18. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19:1639-45; PMID:19541911; http://dx.doi.org/10.1101/gr.092759.109.
19. Hansen RS, Stöger R, Wijmenga C, Stanek AM, Canfield TK, Luo P, et al. Escape from gene silencing in ICF syndrome: evidence for advanced replication time as a major determinant. Hum Mol Genet 2000; 9:2575-87; PMID:11063717; http://dx.doi.org/10.1093/hmg/9.18.2575.
20. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, et al. Differential methylation of tissueand cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41:1350-3; PMID:19881528; http://dx.doi.org/10.1038/ng.471.
21. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi.org/10.1038/ng.298.
22. Tang CSM, Epstein RJ. A structural split in the human genome. PLoS One 2007; 2:603; PMID:17622348; http://dx.doi.org/10.1371/journal.pone.0000603.
23. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129:823-37; PMID:17512414; http://dx.doi.org/10.1016/j.cell.2007.05.009.
24. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001; 410:120-4; PMID:11242054; http://dx.doi.org/10.1038/35065138.
25. Karachentsev D, Sarma K, Reinberg D, Steward R. PR-Set7-dependent methylation of histone H4 Lys 20 functions in repression of gene expression and is essential for mitosis. Genes Dev 2005; 19:431-5; PMID:15681608; http://dx.doi.org/10.1101/gad.1263005.
26. Vakoc CR, Sachdeva MM, Wang H, Blobel GA. Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol 2006; 26:9185-95; PMID:17030614; http://dx.doi.org/10.1128/MCB.01529-06.
27. Heard E, Disteche CM. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev 2006; 20:1848-67; PMID:16847345; http://dx.doi.org/10.1101/gad.1422906.
28. Choi SH, Heo K, Byun HM, An W, Lu W, Yang AS. Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res 2011; 39:104-18; PMID:20841325; http://dx.doi.org/10.1093/nar/gkq774.
29. Rangasamy D, Berven L, Ridgway P, Tremethick DJ. Pericentric heterochromatin becomes enriched with H2A.Z during early mammalian development. EMBO J 2003; 22:1599-607; PMID:12660166; http://dx.doi.org/10.1093/emboj/cdg160.
30. Xie ZH, Huang YN, Chen ZX, Riggs AD, Ding JP, Gowher H, et al. Mutations in DNA methyltransferase DNMT3B in ICF syndrome affect its regulation by DNMT3L. Hum Mol Genet 2006; 15:1375-85; PMID:16543361; http://dx.doi.org/10.1093/hmg/ddl059.
31. Moarefi AH, Chédin F. ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3Bmediated de novo DNA methylation. J Mol Biol 2011; 409:758-72; PMID:21549127; http://dx.doi.org/10.1016/j.jmb.2011.04.050.
32. Ueda Y, Okano M, Williams C, Chen T, Georgopoulos K, Li E. Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development 2006; 133:1183-92; PMID:16501171; http://dx.doi.org/10.1242/dev.02293.
33. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007; 448:714-7; PMID:17687327; http://dx.doi.org/10.1038/nature05987.
34. Hodges E, Molaro A, Dos Santos CO, Thekkat P, Song Q, Uren PJ, et al. Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment. Mol Cell 2011; 44:17-28; PMID:21924933; http://dx.doi.org/10.1016/j.molcel.2011.08.026.
35. Molaro A, Hodges E, Fang F, Song Q, McCombie WR, Hannon GJ, et al. Sperm methylation profiles reveal features of epigenetic inheritance and evolution in primates. Cell 2011; 146:1029-41; PMID:21925323; http://dx.doi.org/10.1016/j.cell.2011.08.016.
36. Zhang Y, Jurkowska R, Soeroes S, Rajavelu A, Dhayalan A, Bock I, et al. Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res 2010; 38:4246-53; PMID:20223770; http://dx.doi.org/10.1093/nar/gkq147.
37. Hu JL, Zhou BO, Zhang RR, Zhang KL, Zhou JQ, Xu GL. The N-terminus of histone H3 is required for de novo DNA methylation in chromatin. Proc Natl Acad Sci USA 2009; 106:22187-92; PMID:20018712; http://dx.doi.org/10.1073/pnas.0905767106.
38. Brinkman AB, Gu H, Bartels SJ, Zhang Y, Matarese F, Simmer F, et al. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res 2012; PMID:22466170; http://dx.doi.org/10.1101/gr.133728.111.
39. Conley ME. Genes required for B cell development. J Clin Invest 2003; 112:1636-8; PMID:14660738.
40. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009; 228:132-48; PMID:19290925; http://dx.doi.org/10.1111/j.1600-065X.2008.00748.x.
41. Yamadori T, Baba Y, Matsushita M, Hashimoto S, Kurosaki M, Kurosaki T, et al. Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein. Proc Natl Acad Sci USA 1999; 96:6341-6; PMID:10339589; http://dx.doi.org/10.1073/pnas.96.11.6341.
42. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA 1973; 70:190-4; PMID:4346033; http://dx.doi.org/10.1073/pnas.70.1.190.
43. Xi Y, Li W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinformatics 2009; 10:232; PMID:19635165; http://dx.doi.org/10.1186/1471-2105-10-232.
44. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.; 1,000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25:2078-9; PMID:19505943; http://dx.doi.org/10.1093/bioinformatics/btp352.
45. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26:841-2; PMID:20110278; http://dx.doi. org/10.1093/bioinformatics/btq033.